Armata Pharmaceuticals (ARMP) director granted 25,640 stock options

Rhea-AI Filing Summary

Armata Pharmaceuticals director Patti Joseph M received a grant of stock options representing rights to acquire 25,640 shares of common stock. The options have an exercise price of $11.61 per share and expire on March 9, 2036. According to the terms, the options will vest in full on March 9, 2027, provided she remains in continuous service through that date. Following this grant, she holds 25,640 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PATTI JOSEPH M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy)	25,640	$0.00	--

Holdings After Transaction: Stock Options (Right to Buy) — 25,640 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATTI JOSEPH M

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CA 90066

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$11.61	03/09/2026		A		25,640		(1)	03/09/2036	Common Stock	25,640	$0.00	25,640	D

Explanation of Responses:

1. The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

	/s/ Joseph M. Patti	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Armata Pharmaceuticals (ARMP) report in this Form 4?

Armata Pharmaceuticals reported a grant of stock options to director Patti Joseph M. She received rights to acquire 25,640 shares of common stock, reflecting a compensation-related award rather than an open-market purchase or sale.

How many Armata Pharmaceuticals (ARMP) stock options were granted to Patti Joseph M?

Patti Joseph M was granted 25,640 stock options. Each option represents the right to buy one share of Armata Pharmaceuticals common stock under the terms disclosed in the filing, subject to vesting and the specified exercise price.

What is the exercise price and expiration date of the ARMP stock options granted?

The granted stock options have an exercise price of $11.61 per share and expire on March 9, 2036. These terms define the cost to acquire each share and the final date by which the options can be exercised.

When do the Armata Pharmaceuticals (ARMP) options granted to Patti Joseph M vest?

The stock options will vest in full on March 9, 2027. Vesting is conditioned on continuous service through that date, meaning she must remain in her role until then for the options to become fully exercisable.

Did the Armata Pharmaceuticals (ARMP) Form 4 show any share sales or purchases?

The Form 4 shows an acquisition through a grant of stock options, not a market trade. It records a compensation-related award of 25,640 options, with no open-market buying or selling of Armata Pharmaceuticals common shares reported.